KBC Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

KBC Group’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-34,159	Closed	-$383K	–	1322
2017 Q3	$383K	Buy	+34,159	New	+$377K	﹤0.01%	1015
2016 Q3	–	Sell	-11,670	Closed	-$152K	–	1323
2016 Q2	$152K	Hold	11,670	–	–	﹤0.01%	1118
2016 Q1	$128K	Hold	11,670	–	–	﹤0.01%	1102
2015 Q4	$107K	Hold	11,670	–	–	﹤0.01%	1111
2015 Q3	$81K	Sell	11,670 -5,914	-34%	-$50.6K	﹤0.01%	1158
2015 Q2	$173K	Sell	17,584 -5,651	-24%	-$51.5K	﹤0.01%	1153
2015 Q1	$206K	Buy	+23,235	New	+$185K	﹤0.01%	1125

KBC Group's SCLN Position: Q4 2017 in Review

KBC Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 34,159 shares — an estimated $383K sold.

KBC Group first reported a position in SCLN in Q1 2015 and held it in 7 quarters. The position peaked at $383K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

KBC Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
KBC Group sold 34,159 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $383K.
KBC Group first reported a position in Sciclone Pharmaceuticals Inc in Q1 2015 and held it in 7 quarters.
KBC Group's Sciclone Pharmaceuticals Inc position peaked at $383K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on KBC Group's 13F filing for Q4 2017, filed 7 Feb 2018.